In fact, recruitment of patients with endometriosis is currently ongoing for a phase II clinical trial to assess the efficacy of a monoclonal antibody targeting IL-33 (MT-2990, Mitsubishi Tanabe Pharma Corporation; https://clinicaltrials.gov/ct2/show/NCT03156738). The gene discussed is IL33; the disease is endometriosis.